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Gene expression3D reconstituted respiratory epithelia have emerged as better in vitro models for toxicological testing
compared to cell lines due to the conservation of key morphological features and functions. MucilAir™
is a commercially available human airway epithelia system that can potentially maintain functional attri-
butes for up to a year, however, detailed mucociliary characteristics and xenobiotic metabolism relevant
to inhaled pro-toxicant bioactivation is lacking. Here, we assessed in MucilAir™ some key biomarkers
that are characteristic of the respiratory epithelia including morphology, function and xenobiotics meta-
bolism. The end points that were measured included targeted proteomics using a panel of 243 airway
surface liquid (ASL) proteins, cilia beat frequency (CBF), a qRT-PCR screen of xenobiotic metabolizing
enzymes, and CYP2A6/13, CYP1A1/1B1 activity. Comparison of ASL proteomics with human sputum iden-
tiﬁed key proteins common to both matrices, but present at different levels. Xenobiotic metabolism gene
proﬁling demonstrated strong similarities with the normal human lung and did not reveal any consistent
changes when assessed over a 6 month period. Inducibility and activity of CYP1A1/1B1 and activity of
CYP2A6/2A13 were present at one month in culture and maintained in one tested MucilAir™ donor for
several months. In conclusion, MucilAir™ presented important morphological and metabolic character-
istics of a mucociliary epithelium in short and long term culture. MucilAir™ is therefore a potentially use-
ful model to test repeated sub-cytotoxic doses of toxicants.
 2015 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
The respiratory epithelium is in direct contact with the environ-
ment and plays a double role as a permeable membrane to facili-
tate gaseous exchanges and as a barrier to protect against
exposure to germs, allergens, and chemical pollutants (Spina and
Page, 1992). Tobacco smoke, occupational and environmental
exposure to chemicals are major driving factors in the develop-
ment of respiratory diseases such as lung cancer and chronic
obstructive pulmonary disease (COPD) (Mitchell et al., 1999). The
respiratory tract is also used as a route for drug delivery for which
safety evaluation is required. The metabolism of inhaled chemicals
can contribute to their toxic activity; this process of metabolic
transformation of a given chemical, also named pro-toxicants, into
a reactive species is known as bioactivation (Castell et al., 2005).Well documented examples of enzyme-driven bioactivation of
inhaled pro-toxicants include the formation of DNA reactive spe-
cies such as:
(i) diol-epoxides from CYP1A1-dependent oxidation of ben-
zo[a]pyrene (B[a]P) found in tobacco smoke and exhaust
fumes (Uppstad et al., 2010),
(ii) diazo groups resulting from the a-hydroxylation of tobacco
nitrosamines by the CYP2A enzyme family (Brown et al.,
2007),
(iii) formaldehyde hydrate as a by-product from the glutathione
conjugation through inhalation of dichloromethane vapors
(Hashmi et al., 1994).
The toxicological assessment of inhaled chemicals is limited
however by the availability of physiologically relevant and robust
in vitro models. Two key requirements for such models are (i) to
maintain normal airway mucociliary epithelia characteristics to
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enzyme activity over time, allowing both the assessment of chemi-
cals for acute and repeat exposure. We and others have previously
shown that the columnar epithelia morphology and the expression
of the xenobiotic metabolizing enzymes, CYPs, is either lost or lim-
ited in lung derived cell lines such as BEAS-2B, A549, Calu-1, HAEO,
and NCI-H292 (Courcot et al., 2012; Garcia-Canton et al., 2013).
This could possibly lead to false negative results when assessing
the toxicity of inhaled chemicals. In contrast, 3D cultures of pri-
mary lung epithelial cells have shown greater potential to retain
normal morphology, metabolic gene expression and metabolic
competency (Newland et al., 2011; Reus et al., 2014). The culture
of differentiated human bronchial epithelial cells (HBECs) surgi-
cally resected from bronchial tissue were ﬁrst described in 1996
and showed; (i) polarized mucociliary differentiation with airway
surface liquid (ASL) mucus secretion, and (ii) good similarity for
metabolic gene expression compared to normal lung tissue (Gray
et al., 1996). Furthermore, mixed oxidase metabolic activity was
detected in this cell model at 7 and 28 days in culture (Newland
et al., 2011). There are currently different commercially available
respiratory epithelia cultures emulated from the original HBECs
model described by Gray and colleagues, notably EpiAirway™ from
MatTek and MucilAir™ from Epithelix. These systems form a polar-
ized columnar epithelia when maintained at the air liquid interface
(ALI) on transwell porous membranes, in which basal, mucus pro-
ducing, and ciliated cells can be distinguished (Chemuturi et al.,
2005; Crespin et al., 2011; Gray et al., 1996).
EpiAirway™ are tracheobronchial cells that can be maintained
at the ALI for up to a month according to the manufacturer
(MatTek Corporation, 2014). The mucociliary characteristics of
the EpiAirway™ model have been studied to some extent and
reported in the literature. Proteomic analysis of the airway surface
liquid of EpiAirway™ has revealed that the major functional class
of protein secreted were involved in immunity, signaling, cell
adhesion and structure and included key markers of mucociliary
phenotype such as the MUC proteins (Ali et al., 2011). Some xeno-
biotic metabolizing enzyme activity has also been reported for
EpiAirway™. For instance, CYP1A1 activity was detectable in
EpiAirway™ after induction but no activity was reported when
CYP2D6, 3A4, 2C9, and 2E1 were tested (Bolmarcich et al., 2010;
Hayden et al., 2006).
MucilAir™ is reconstituted from human nasal or bronchial
biopsies (Epithelix Sarl, 2006). It is claimed that MucilAir™ can
remain in a homeostatic culture state for a long period of time, pos-
sibly up to a year, potentially allowing repeated exposures
(Epithelix Sarl, 2006). The metabolic capability of this cell system
however has never been evaluated either in short or long term cul-
ture. Therefore, it is unclear whether MucilAir™ would adequately
model adverse biological effects associated with exposure to toxi-
cants requiring bioactivation.
Adequate characterization of an in vitro system is a key require-
ment to evaluate to what extent such a system is relevant for tox-
icological testing. Our objectives are therefore to characterize:
(i) the mucociliary phenotype of MucilAir™ using a targeted
proteomics approach and a microscope-based measurement
of cilia beat frequency.
(ii) the metabolic competency of MucilAir™ for key enzymes
known to be involved in the bioactivation of inhaled pro-
toxicants tested in short term cultures and in cells main-
tained in culture for up to 6 months by qRT-PCR and activity
assays.
Here we report our ﬁndings and contrast the results with nor-
mal human sputum and in vitro systems including HBECs,
EpiAirway™ and the cell line H292.2. Materials and methods
2.1. Cell culture
The MucilAir™ cell inserts were purchased from Epithelix Sarl
(Plan-Les-Ouates, Switzerland). The cells were maintained in
proprietary MucilAir™ culture medium at 37 C and 5% CO2 in a
humidiﬁed incubator. The EpiAirway™ cell inserts were purchased
from MatTek Corporation (Ashland, MA, USA). Cells were
maintained in proprietary EpiAirway™ assay medium at 37 C
and 5% CO2 in a humidiﬁed incubator. Human bronchial epithelial
cells (HBECs) from three non-smokers males were obtained
from Lonza (Basel, Switzerland) and cultured in 50% BEBM
(Lonza Group Ltd, Basel, Switzerland), 50% DMEM with
supplements as described previously (Maunders et al., 2007).
Each cell donor for each primary cell system used in this study
were labeled with individual numbers. Culture time points
mentioned in this study refer to days post-delivery of the cells
for MucilAir™ and EpiAirways™. HBECs were used at 28 days after
seeding into transwells which is the required time to reach full
mucociliary differentiation for this airway model. The human
hepatocarcinoma-derived cell line (HepaRG) was purchased as
vials of cryopreserved differentiated cells from Biopredic
International (Saint-Gregoire, France). The cells were maintained
on 24 well culture plates (Corning, NY, USA) coated
with 0.03 mg/ml PureCol bovine collagen solution (Nutacon, The
Netherlands) with the media supplied by the manufacturer.
The human pulmonary mucoepidermoid carcinoma cell line
NCI-H292 was purchased from ATCC (Manassas, VA, USA) and seeded
onto 12 well plates (Costar 3513) (Corning incorporated, NY, USA) at
1  105 cells/ml. The cells were maintained in RPMI cell culture
medium (ATCC, Manassas, VA, USA) supplemented with 10% foetal
calf serum and 50 U/ml penicillin streptomycin.2.2. Proteomics of the airway surface liquid (ASL)
The MucilAir™ cell inserts were washed with 200lL phosphate
buffered saline (PBS) pH = 7.4 approximately every 4 weeks. The
PBS was collected and stored at 80 C. Sputum from 10 non-
smokers (Soﬁa Bio, Soﬁa, Bulgaria, study code SB-SC_v1) and
MucilAir™ ASL were thawed, centrifuged and ﬁltered using a
0.2 lm ﬁlter plate (PALL Corporation, Port Washington, NY, USA).
Total protein in the samples was quantiﬁed using the bicinchoninic
acid (BCA) microassay. 50 lg of protein was prepared for mass
spectrometry analysis. The samples were denatured in ammonium
bicarbonate and tetraﬂuoroethylene (TFE) and then digested over-
night with trypsin (1:10, Promega, Southampton, UK). After the
digestion was complete, the samples were desalted using 96-well
C18 desalting plates (Empore, St Paul, MN, USA), transferred into
96-well plates and vacuum evaporated. The trypsin-digested sam-
ples were resolubilized with 30 lL of a reconstitution solution
including 5 internal standard (IS) peptides. Prior to sample analy-
sis, a Multiple Reaction Monitoring (MRM) mass spectrometry
assay was developed using synthetic peptides covering an array
of 243 proteins selected from a discovery step. 5 lL (2.5 lg) of
material was injected per sample onto a NanoAcquity UPLC
(Waters, Elstree, UK) coupled to a 5500 QTRAP mass spectrometer
(AB Sciex, Framingham, MA, USA). For the MRM assay, the optimal
2 transitions per peptide were acquired using selected reaction
monitoring (SRM)-triggered MS/MS on a QTRAP 5500 instrument.2.3. Statistical analysis of MRM protein data
All statistical analysis and graphical plotting was undertaken
using Gene Spring 13 (Agilent, Santa Clara, CA, USA) with Mass
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that a number of proteins were only expressed in a subset of sam-
ples which would skew subsequent statistical conclusions.
Therefore a 75% frequency ﬁlter was applied. This resulted in 163
of 171 MucilAir™ proteins and 134 of 135 human sputum proteins
being included into subsequent data analysis. Principal
Components Analysis (PCA) was undertaken using the NIPAL S
algorithm on Mean Cantered and Scaled data values. Hierarchical
Cluster Analysis (HCA) was performed using data values normal-
ized by the average intensity with the clustering distance based
on Euclidean similarity and Ward’s linkage rule. The convention
used for the heat map is red for high protein level and green for
low protein abundance.
2.4. Cilia beat frequency (CBF) measurement (Sisson Ammons Video
Analysis)
Cellular cilia beat frequency (CBF)(Hz) was quantiﬁed using the
SAVA-system (Sisson Ammons Video Analysis) (AmmonsTable 1
Summary of assays performed with reconstituted airway epithelia at different time poi
xenobiotic metabolizing enzymes, and activity assays for selected CYPs. The primary cel
MucilAir™ and EpiAirway™ are post-delivery from the supplier. HBECS were grown and d
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ASL proteomics time
points
MucilAir
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MucilAir
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MucilAir
M417
mRNA qRT-PCR single
time point
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M360
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MucilAir
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MucilAir
M417
j
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EpiAirway E1 j
EpiAirway E2 j
EpiAirway E3 j
mRNA qRT-PCR
multiple time points
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M360
.
MucilAir
M370
.
MucilAir
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.
CYP2As activity single
time point
MucilAir
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.
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M345
.
MucilAir
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.
CYP1A1/1B1 activity
single time point
MucilAir
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.
MucilAir
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.
MucilAir
M417
.
CYP2As activity single
time point
14 MucilAir .
Donors + pool
CYP2As activity
multiple time points
MucilAir
M360
.
CYP1A1/1B1 activity
multiple time points
MucilAir
M360
.engineering, Clio, MI, USA) which comprises an inverted AX 10
microscope (Zeiss, Gottingen, Germany) ﬁtted with a heated XL
multi S1 Plexiglas chamber (Pecon, Erbach, Germany) coupled to
a high-speed digital video camera (Carl Zeiss, Gottingen,
Germany). The microscope chamber temperature is maintained
at 37 C during the image acquisition process. For each donor
and each insert, we acquired a 4.3 s movie of a large microscopic
ﬁeld (100 magniﬁcation, 10 ocular, 10 objective).
2.5. RNA extraction, reverse transcription and qPCR
Total RNA was isolated from cells using the RNeasy mini kit
(Qiagen, Manchester, UK). The RNA quantity was measured using
a NanoDrop ND1000 spectrophotometer (NanoDrop
Technologies, Wilmington, DE, USA) and the quality assessed with
an Agilent 2100 Bioanalyzer (Agilent, Wokingham, UK). A pool of 5
human lung RNA was purchased from Biochain (Newark, CA, USA),
the smoking history of the subjects was not known. The RNA
(40 ng/ll) was converted to cDNA using the high-capacity cDNAnts. The 3 assays performed included ASL proteomics, qRT-PCR of genes coding for
l donor number is indicated together with the days of samples collection. Days for
ifferentiated in house.
8 31 59 82 87 98 113 115 126 143 154 173 192 204
d d d d
d d d d
d d d d
. .
. .
. .
. . . . . .
. .
Fig. 1. Proteomic comparison of MucilAir™ ASL and healthy human subjects induced sputum. (A) Venn Diagram of the differential occurrence proteins between MucilAir™
(red) and human induced sputum (blue) sputum samples. A 75% frequency ﬁlter was applied to the detected proteins initially imported from the MRM data, resulting in 163
MucilAir™ and 134 human sputum proteins being selected and plotted. (B) Principle Components Analysis of MucilAir™ ( ) and human sputum ( ) using the 163 proteins
ﬁltered. PC1 are plotted and explained 46.13% and 13.26% of the total variance respectively. Data was mean cantered and scaled prior to running the analysis. The T2 Hotelling
Elipse at 95% is plotted (solid circle). (C) Hierarchical clustering of the 112 protein common between MucilAir™ and human induced sputum (ISputum) proteins. A combined
tree is plotted for protein proﬁle across both sample sets has been normalized by the average intensity with the clustering distance (show at true scale) and based on
Euclidean similarity and Ward’s linkage rule. Red indicates high level of expression, green indicates low level of expression.
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USA). qPCR was carried out using custom TaqMan array 96-well
plates and TaqMan Fast Universal Master mix (Applied
Biosystems, Foster City, CA, USA). Each plate contained 1 manufac-
turing control, 5 endogenous controls and 40 pre-selected metabo-
lism-related genes. Ampliﬁcation was performed with the fast PCR
7500 (Applied Biosystems, Foster City, CA, USA).
2.6. Gene expression data analysis
After completion of the qPCR, the threshold cycle (Ct) values
were visually inspected using the fast PCR 7500 software v.2.0.5.
When required, the threshold setting default (0.2) was manually
adjusted to ensure optimal sensitivity was maintained. All Ct val-
ues >36, indicative of the plateau phase of qPCR, were considered
non-expressed genes. The Ct values were then normalized against
the selected endogenous control genes B2M, GAPDH and RPLPO to
generate DCt values (Ct gene of interest – Ct endogenous control
gene).
JMP Genomics 6.0 (SAS, Cary, NC, USA) and Gene Spring GX 13
(Agilent, Santa Clara, CA, USA) were used to perform the gene
expression graphical and statistical analysis. Principal Component
Analysis (PCA) and hierarchical clustering were selected for graphi-
cal representations. For the hierarchical clustering algorithm,
Ward’s minimum variance method was selected for interpretation
of the normalized gene expression data (DCt). The convention used
for the heat map is red for high expression and green for low
expression. Any additional data procedures applied are indicated
in ﬁgure legends.
2.7. CYP activity assay
CYP1A1/1B1 activity was measured using the P450-Glo™ kit
(Promega, Southampton, UK). The probe used was Luciferin 60
chloroethyl ether (luciferin-CEE) (50 lM) added directly to the
basal medium (4 h incubation). For induction, cells were pre incu-
bated for 48 h with 10 nM of TCDD (Sigma, Gillingham, UK). For
inhibited conditions, a-naphthoﬂavone (Sigma, Gillingham, UK)
(20 lM) was added to the basal medium with the probe. After
the incubation, the luminescence was measured using a
Spectramax M3 plate reader (Molecular Devices, New Milton,
UK). For the CYP2A6/2A13 activity assay, coumarin (Sigma,Fig. 2. Pie chart of protein classes common to both human sputum aGillingham, UK) (50 lM) was used as a probe and 8-methoxypsor-
alen (8-MOP) (Sigma, Gillingham, UK) (25 lM) as an inhibitor. The
metabolite measured was 7-hydroxycoumarin (7OH-coumarin).
After the probe incubations (16 h), the basal medium was removed
and the pH adjusted to pH 5.0 with 1 M hydrochloric acid and trea-
ted with 1.6 lL of b-glucuronidase from Helix pomatia (Sigma,
Gillingham, UK) for 1 h at 37 C while shaking. Once the glu-
curonidase treatment was ﬁnished, 1 volume of ice cold methanol
was added and the samples stored at 20 C. The solvent was
removed at 45 C on a rotary evaporator (Eppendorf AG,
Hamburg, Germany) and then reconstituted with 500 lL 30% ace-
tonitrile: water. The samples were ﬁltered through a 0.2 lm
Mini-UniPrep™ Syringeless ﬁlter device (Whatman, Chalfont St
Giles, UK). The metabolites were then quantiﬁed against a 7-hy-
droxycoumarin (Sigma, Gillingham, UK) calibration curve using a
UPLC-AB SCIEX/API 4000 Q-Trap mass spectrometer (Applied
Biosystems, Framingham, MA, USA) and a Kinetex 2.6 lm PFP,
100 Å UPLC column (Phenomenex, Macclesﬁeld, UK) HepaRG cells
were used as ‘positive control responders’ in both assays.
2.8. Protein extraction and quantiﬁcation
The media was removed and the cells then lysed with 150 lL
M-PER (Mammalian Protein Extraction Reagent) (Thermo
Scientiﬁc Inc, Rockford, IL, USA). The protein content was measured
using the BCA protein assay (Thermo Fisher Scientiﬁc Inc, Rockford,
IL, USA) together with a Spectramax M3 plate reader (Molecular
Devices, New Milton, UK).
2.9. Experimental design summary
MucilAir™ were selected to perform ASL proteomics, metabolic
gene expression analysis, and CYP activity assays in both short
term and long term cultures because it is the only system which
is claimed to have a shelf-life of at least a year (Epithelix Sarl,
2006) and for which little data is available on metabolic compe-
tency. EpiAirways™ have a recommended shelf-life of a month
(MatTek Corporation, 2014), whilst in our hands, HBECs cannot
be maintained for more than three weeks post-differentiation,
therefore these cells were only used on occasion in this study.
Table 1 summarizes the 3 assays performed with the different pri-
mary cell models, namely, ASL proteomics, qRT-PCR, and CYPsnd MucilAir™ ASL (112 prot) based on Panther genes ontologies.
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was performed along with the cell type and donor number is given.
As indicated earlier, days for MucilAirTM and EpiAirwaysTM are
post-delivery. For HBECs days refer to the time post-seeding of
the cells on transwell inserts. The results presented in this paper
follow the same sequence as shown in Table 1. The experimental
timeline was determined as follows: ASL was collected from day
98 onwards. A minimum of two weeks was given between each
collection time point to allow for sufﬁcient material to accumulate
on the apical surface of the MucilAir™ culture. No sample was col-
lected at an earlier time point as the MRM proteomics assay had
not been validated yet and sample stability could have been com-
promised by storage. All early single time points for mRNA extrac-
tion and CYP activities were selected within a 30 day window post-
delivery of the culture inserts for MucilAir™ and EpiAirways™ and
28 days differentiation for HBECs based on the time windowwhere
those systems are typically used (MatTek Corporation, 2014;
Maunders et al., 2007). Time course for mRNA extraction and
CYPs activity was planned for a period of six months which was
considered a reasonable period due to possible technical chal-
lenges about long term culture of primary airway cells such as
potential for contamination. For CYP2A enzymes activity, the same
inserts were used throughout the time course. CYP2As activity was
typically measure on a 28 days interval basis except for the ﬁrst
interval done at 14 days to test an early time point. The last
CYP2As measurement was performed early (11 days interval) due
to change in the culture morphology which is discussed later.
Fewer time points were used for CYP1A1 activity since TCDD
causes irreversible toxicity for the culture and therefore more time
points would have required a considerable number of inserts.Fig. 3. ASL protein expression and cilia beat frequency (CBF) over time. (A) Principle
Component Analysis of MucilAir™ protein panel (163 proteins) at time points 98-
days (j), 126-day (N), 154-day (d), and 204-days (+). PC1 and PC2 are plotted and
explain 28.95% and 26.36% of the total variance respectively. The data was then
mean centered and scaled prior to running the analysis. The T2 Hotelling Elipse at
95% is plotted (solid circle). (B) Mean CBF (Hz) measured every two weeks in
MucilAir™ in three donors M360, M370, and M417 based on measurements
obtained from a minimum of 3 distinct areas for each subject (SDs are shown for
each time point). CBF statistically different (95% conﬁdence interval) from the
reference CBF from each donor at day 3 are marked by an ‘‘⁄’’.3. Results
3.1. Mucociliary phenotype characterization – ASL proteomics
To characterize the mucociliary phenotype of the MucilAir™
cultures, a targeted proteomic assay was applied to the ASL
secreted by the cells. An MRM assay was developed with a total
of 243 protein candidates compiled from the literature and
exploratory studies on normal human sputum. ASL samples pooled
by subjects and collected at days 98, 126, 154, and 204 were ana-
lyzed by LC-MS/MS and compared with induced sputum from 10
non-smoker donors. 171 of the 243 proteins included in the
MRM assay were detected in the MucilAir™ cultures from 3 donors
(M360, M370, M417). The protein proﬁles appeared to be some-
what heterogeneous, as in no case was there a protein in the
MucilAir™ MRM set that occurred in every sample at every time-
point. Because of this heterogeneity a statistical ﬁlter was applied
whereby only proteins that occurred in at least 75% of the samples
in either MucilAir™ or sputum were considered. The resulting 163
MucilAir™ ASL proteins were compared with the resulting 134
human sputum proteins and a strong overlap of 112 common pro-
teins was found (Fig. 1A and Supplementary Table 1). PCA based on
the mean level of expression of the 112 proteins between human
sputum and MucilAir™ ASL revealed, however, that the two matri-
ces are distinct (Fig. 1B). The heat map presented in Fig. 1C clearly
illustrates the differences in protein levels. Protein classes ontolo-
gies for the 112 proteins in common between human sputum and
MucilAir™ are presented in the pie-chart in Fig. 2. To further inves-
tigate any changes in the MRM derived protein proﬁle that might
be associated with the MucilAir™ culture age, a PCA analysis was
performed on the same data set split by time points (Fig. 3A).
PC1 and PC2 accounted for 55.33% total variance and there was
no evidence of culture age related differences (Fig. 3A). As this is
only just over half the total variance, higher dimension PC werealso examined and this indicated that there might be differences
in the protein proﬁles of days 154 and 204 compared to day 98.
To investigate this further an ANOVA was performed on day 98
versus paired condition of day 154 and 205 speciﬁcally. From this,
11 proteins were initially indicated to have statistically signiﬁcant
fold changes (at p = 0.05) (data not shown). However, the power
calculation applied during this procedure indicated that 8 of these
proteins could be expected to have statistically signiﬁcant fold
changes purely by chance. Therefore, a further ANOVA including
a multiple testing correction (Bejamini-Hochberg Faulse
Discovery Rate) was then applied. From this only one of the 8 pro-
teins (Nucleobinding-1) was highly signiﬁcantly down regulated at
day 154 but not at day 204. Therefore, taken together the results
indicate there was no time effect on the ASL proteomic proﬁle.
As part of the apical surface microenvironment assessment of the
CBF was conducted every two weeks from day 3 post-delivery to
day 157 in MucilAir™ with 3 subjects (M360, M370, M417). A
870 A. Baxter et al. / Toxicology in Vitro 29 (2015) 864–875downward trend was observed over time (Fig. 3B). A Dunnett test
at 95% conﬁdence interval with the ﬁrst CBF time point (day 3) as
reference indicated however that only day 87 and 143 were signiﬁ-
cantly different from the reference in subject M370 and M417,
respectively (Fig. 3B).3.2. Metabolic gene expression – single time point
One of the objectives of our study was to assess the metabolic
competency of MucilAir™ cells. To achieve this a quantiﬁcation
by qRT-PCR was undertaken using a panel of 40 metabolic enzyme
encoding genes in MucilAir™ (3 donors, 10 days post-delivery,
M360, M370, M417), HBECs (3 donors, 28 days in culture, HBECs
1, 2, and 3), and EpiAirway™ (3 donors, 9 days post-delivery, E1,
2, and 3). Pooled human lung RNA (HL pooled) was used as a con-
trol and NCI-H292 RNA was used as an example of immortalized
human lung epithelial cell. The control cells were compared to cells
which had been pre-incubated with 2,3,7,8 tetrachlorodibenzo-p-
dioxin (TCDD) for 72 h, an inducer of CYP1A1 and CYP1B1. PCA
was conducted to identify cell types that cluster based on similari-
ties of their metabolic gene expression proﬁles. The PCA plot
showed clear discrimination between the cell line NCI-H292 and
the different 3D primary cell (Fig. 4). The cells were also grouped
by induction status (Fig. 4). The unsupervised hierarchical cluster
shown in Supplementary Fig. 1 was generated to visualize the
expression data for each individual gene in each individual cell
type and for each subject. Clear induction of CYP1A1 and CYP1B1
is observed in all cell types after TCDD treatment. Furthermore,
expression of speciﬁc respiratory epithelium CYPs such as
CYP2F1, CYP3A5, and CYP2A13 were detected in primary cells
(Supplementary Fig. 1).Fig. 4. Principal Component Analysis comparing the similarities in the expression of 40 m
(red) (3 subjects: M360, M370, and M417), EpiAirway™ (green) (three subjects: E1, E2, E
and pooled human lung RNA (N) (ﬁve donors). Clusters of induced and non-induced air3.3. Metabolic gene expression at multiple time points
A further objective of this study was to follow the metabolic
gene expression proﬁles of independent cultures of MucilAir™
over time. RNA was extracted from MucilAir™ obtained from
three donors (M360, M370, M417) maintained in culture for
23, 113 and 173 days after delivery. The quantiﬁcation by qRT-
PCR of the panel of 40 metabolic enzyme encoding genes was
repeated. PCA was performed on the Ct normalized data. PC1
and PC2 were plotted (representing 40.27% and 18.22% of the
total variance respectively). No clustering based on time points
could be observed (Fig. 5A and B). Some clustering was based
on subject highlighting inter-individual differences between
donors (Fig. 5B).
3.4. CYP1A1/1B1 and CYP2A6/2A13 activity – single time point
The activities of a pair of key cytochrome P450 enzymes
(CYP1A1/1B1, CYP2A6/2A13) involved in the oxidative metabolism
of inhaled toxicants were further evaluated in MucilAir™ at a sin-
gle early time point since positive gene expression is not always
synonymous of protein activity. To assess the CYP1A1/1B1 activity,
Luc-CEE, a CYP1A1/1B1 luminogenic probe substrate, was added to
the culture media of non-induced cells (donors M360, M370,
M417) and cells pre-incubated with 10 nM TCDD for 48 h, a known
inducer of CYP1A1/1B1. Coumarin was used with MucilAir™
(donors M343, M345, M347) as a probe substrate for CYP2A6/
2A13 and the reaction product 7OH-coumarin was measured after
glucuronidase treatment. a-naphthoﬂavone and 8-methoxypsora-
len are inhibitors of CYP1A1/1B1 and CYP2A6/2A13 respectively
and were used to conﬁrm the enzyme – probe speciﬁcity. Three
subjects were tested to account for possible interindividualetabolic genes in both non-induced (d) and induced (TCDD 10 nM) (j) MucilAir™
3), HBECs (purple) (three subjects: HBECs1, 2, and 3), H292 cells (blue) (triplicates)
way epithelia cultures have been circled.
A. Baxter et al. / Toxicology in Vitro 29 (2015) 864–875 871variability and HepaRG were included in the experimental design
as a hepatoma cell line which is known to express a range of meta-
bolic enzymes (Andersson et al., 2012). Each group of tested
enzymes showed signiﬁcantly higher activity in the MucilAir™
probe group for CYP2A6/2A13 and in the MucilAir™ induced group
for CYP1A1/1B1 compared to the inhibited group (Fig. 6A and B).
The CYP1A1/1B1 activity appeared lower in TCDD treated
HepaRG but was still approximately 20-fold higher than in non-in-
duced HepaRG indicating the hepatoma cell line was also positive
for the activity assay. To further assess the interindividual differ-
ences in metabolic competency of MucilAir™ we compared theFig. 5. Xenobiotic metabolizing genes’ expression at multiple time points. (A) Principle
from 3 separate donors, M360 (j), M370 (N), M417 (d); at time-points, 23-day (red), 113
PC2 are plotted and explain 40.27% and 18.22% of the total variance respectively. The
metabolic genes’ expression for MucilAir™ at multiple time points (day 23, day 113, a
samples and gene proﬁles is simultaneously plotted using combined trees, normalized b
branch length is show at arc secant scale for optimal visualization.coumarin 7-hydroxylation activity in cultures derived from a
new set of 14 subjects and the equivalent pooled donor culture.
CYP2A6/2A13 activity was present in most subjects but, as would
be expected with primary cultures, a clear interindividual variabil-
ity was also observed (Fig. 7).
3.5. CYP1A1/1B1 and CYP2A6/2A13 activity – multiple time points
A semi quantitative time course evaluation of CYP2A6/2A13 and
CYP1A1/1B1 activity was conducted by maintaining cells in culture
for one subject (M360) for a period of 154 and 196 days,Component Analysis of MucilAir™ cells xenobiotic metabolizing genes’ expression
-days (blue), and 173-days (green). The data was mean centered and scaled. PC1 and
T2 Hotelling Ellipse at 95% is plotted (solid circle). (B) Hierarchical clustering of
nd day 173). Samples are labeled by subject and time points. Similarity between
y the average intensity, based on Euclidean similarity and Ward’s linkage rule. Tree
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Fig. 6. CYP1A1/1B1 and CYP2A6/2A13 activity in MucilAir™ at 18 and 13 days in
culture, respectively. (A) Luc-CEE oxidation in TCDD induced (10 nM, 72 h) and
non-induced MucilAir™ cells from three subjects (M360, M370, M417) at day 18.
a-naphthoﬂavone (20 lM) was used as CYP1A1 inhibitor. HepaRG were used as an
hepatoma cell line control for CYP1A1 activity after TCDD induction. (B) Coumarin
7-hydroxylation activity measured in MucilAir™ culture from three subjects (M343,
M345, M347). 8-methoxypsoralen (8-MOP) (25 lM) was used as inhibitor control
for CYP2A activity and HepaRG cells were used as positive control cells. All results
are presented as a mean value of three independent measurements with standard
deviations.
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of the ciliated phenotype and based on pre-screening indicating
that CYP2A activity was within the average range of activity in
MucilAir™. This experiment was considered not to be quantitative,
since it was not normalized by total protein content due to the fact
that the cells were reused at each time point for the CYP2A6/2A13
assay. Therefore the objective was to qualitatively assess the pres-
ence or absence of enzyme activity relative to conditions where
enzymes were inhibited. The enzyme activity was recorded follow-
ing the same protocol as described earlier. Fig. 8A presents the data
for CYP1A1/1B1 activity whilst Fig. 8B presents the results for
CYP2A6/13. Inducibility of CYP1A1/1B1 was maintained at the
three time points tested (14, 82, and 196 days) (Fig. 8A) whilst
activity of CYP2A6/2A13 was observed at least up to day 143
(Fig. 8B).
4. Discussion
Investigation of metabolic competency is a key requirement
for toxicology testing when working with in vitro models since
many chemicals are biologically activated. Furthermore, most
toxic stresses are the result of repeated exposure to low doses
of toxicants over a prolonged period of time. Therefore as a
replacement to animal testing there is a need for in vitro models
with (i) adequate morphology to reﬂect the normal exposure
route and (ii) metabolic competency that is maintained for a pro-
longed period of time to allow bioactivation. MucilAir™ cells have
been identiﬁed as a potential model of the human respiratory
epithelia in the ﬁeld of in vitro toxicological testing of inhaled
toxicants. However, to date the morphology, metabolism, gene
expression and longevity in culture have not been thoroughly
investigated. Here, we maintained MucilAir™ in culture for up
to 6 months and assessed the expression of proteins and meta-
bolic genes to study the maintenance of the cultures characteris-
tics at different time points.
A targeted MRM proteomics screen for 243 proteins selected
from a literature search on normal human sputum and other
in vitro studies was developed and applied to the ASL of
MucilAir™ from three donors. We ﬁrst compared the proteomic
proﬁle of sputum from healthy non-smokers with the ASL of
MucilAir™. 163 proteins were detected in 75% of the ASL samples
of MucilAir™ cells from 3 donors (pool of 4 time points) of which
112 (Supplementary Table 1, Fig. 1) were in common with proteins
detected in sputum from 10 non-smokers. Those included markers
of mucociliary differentiation such as proteins of the mucin family
with MUC5B a key protein produced as a result of mucociliary dif-
ferentiation (Gray et al., 2001; Thornton et al., 2000). We also iden-
tiﬁed MUC1, MUC16, and MUC20 which have been reported in a
previous similar comparison between human sputum and HBECs
cultures (Kesimer et al., 2009; Thornton et al., 2000). Ontology
mapping based on protein class indicated that hydrolases, pro-
teases, phosphatases, and oxidoreductases were the most repre-
sented groups of proteins in common between the two matrices
(Fig. 2). When compared to proteomic results from HBECs reported
by Ali et al. (2011), many proteins were overlapping such as cal-
cium binding proteins of the S100-A family, proteases, and protein
of the complement indicating an anti-inﬂammatory and anti-mi-
crobial role. Many of the proteins detected in MucilAir™ by our
proteomics assay include markers such as aldehyde dehydrogen-
ase (AL3A1), peroxiredoxin (PRDX), Serpins (SPBs), S100 proteins
(S10A1, A2, A8), PIGR and others that are known to be up or down
regulated in inﬂammation and COPD (Franciosi et al., 2014; Pelaia
et al., 2014). Therefore, this proteomics panel could be used to map
perturbations in the secreted protein proﬁle following exposure to
toxicants or complex mixtures such as cigarette smoke to evaluateadverse biological effects in vitro. However the correlation between
in vitro data and clinical data might not be straightforward and
caution is advised in interpreting such results. Indeed, principal
component analysis performed on the 112 proteins found in both
matrices, indicated that the expression levels of the ASL proteins
in MucilAir™ were very different from human sputum (Fig. 1C).
Amongst others MUC5B was present but at low abundance in
ASL compared to sputum. Such differences in proﬁles have also
been reported previously with HBECs ASL compared to sputum
(Ali et al., 2011; Kesimer et al., 2009). Human sputum collection
involved sputum induction with a nebulized saline solution, there-
fore it can be expected that the resulting matrix would be different
than mucus spontaneously secreted from a cell culture.
Furthermore, normal sputum would also contain secretion from
immune cells, alveolar type II cells, and serous proteins which
would further contribute to the differences between the twomatri-
ces (Kesimer et al., 2009). In addition, early time point ASL samples
were not collected, so it is not possible to conﬁrm to what extent
the proteomic proﬁle has evolved compared to fresh culture.
However, based on our experimental design, we could not decisi-
vely conclude that the protein proﬁle was signiﬁcantly altered with
age of the cultures over the period from 90 to 200 days (Fig. 3A).
Another endpoint of the apical microenvironment in MucilAir™
cultures is cilia beat frequency (CBF). We measured the CBF over
a period of 157 days and observed a descending trend, but sta-
tistical signiﬁcance was only reached on occasion (Fig. 3B). It is
possible that a longer assessment period would have eventually
lead to a marked decrease in CBF. This evolution could be the result
of a suboptimal humidity in our incubator which leads to a pro-
gressive alteration of the culture phenotype (Horstmann et al.,
1977). We measured the humidity level of our incubator and
obtained values of 88–90% which is a standard reading. The lower
respiratory tract maintains a relative humidity of 100% whilst the
relative humidity of the upper respiratory tract is around 95%
although this can be lower during inhalation (Irlbeck, 1998;
McFadden, 1992). Since our MucilAir™ were of nasal origin, it is
unclear to what extent the humidity level of our incubator could
have a long term impact on our cell culture phenotype but we
would recommend keeping the humidity as close as possible to
95%. This highlights the need to establish the optimal humidity
conditions to ensure long term maintenance of the culture pheno-
type. It was also noted that the mean CBF calculated from all the
time points was signiﬁcantly different (p < 0.05) between the three
subjects. Such variability was reported in fresh nasal brushing from
19 subjects (Veale et al., 1993). Those differences are expected to
be greater when comparing groups of healthy and diseased sub-
jects as it is the case for COPD patients (Yaghi et al., 2012).
Therefore CBF is a useful marker of respiratory epithelia stress
whether it is caused by chemical exposure or by pathogens.
Next, we proﬁled the expression of 40 metabolic genes coding
for proteins relevant to the metabolism of xenobiotics. We ﬁrst
compared the expression proﬁles of MucilAir™ cultures (10 days
post-delivery) with other 3D mucociliary cultures, including
HBECs at ALI (28 days) and EpiAirways™ (9 days post-delivery).
PCA analysis performed on the gene expression proﬁle placed the
MucilAir™, HBECs and EpiAirway™ in three clusters (Fig. 4).
MucilAir™ and EpiAirway™ were closest to the pooled lung sam-
ple. Not surprisingly, the primary cultures formed a distinct cluster
from the cell line NCI-H292. Induction of CYPs with TCDD also lead
to a similar group separation. The human lung expression proﬁle
was distinct by sitting between the induced and non-induced pri-
mary cell cultures (Fig. 4). This sample (supplied by Biochain) was
a pool of mRNA obtained from 5 biopsies for which the smoking
status of the subject was unknown. However, based on the smok-
ing demography, it is possible that one or more subjects in the
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instance induction of CYP1A1 expression (Thum et al., 2006).
Further hierarchical clustering showing individual gene expression
indicated that 3D cultures of primary cells derived from the
respiratory tract have relatively similar expression proﬁles whilst
the cell line NCI-H292 expressed fewer metabolic genes
(Supplementary Fig. 1). In all the tested cell cultures, TCDD was a
strong inducer of CYP1A1. CYP1B1 was also induced but to a lesser
extent due to a higher background expression level compared to
CYP1A1. This is similar to our previous observation with HBEC cul-
tures (Newland et al., 2011). Inspection of the heat map
(Supplementary Fig. 1) pointed to some key differences between
MucilAir™ and the two other primary cell types. Notably
CYP2A13 was expressed at a much higher level in all the
MucilAir™ cultures (Supplementary Fig. 1). This is an important
difference since CYP2A13 is suspected to be a major contributor
to the activation of inhaled toxicants such as tobacco nitrosamines
(Chiang et al., 2011). This difference can be attributed to the point
of origin of the cells in the respiratory tract. EpiAirway™ and
HBECs are derived from the bronchial epithelium, whilst the
speciﬁc type of MucilAir™ used in this study was obtained by nasal
scraping. It has been reported that CYP2A13 is highly expressed in
the upper respiratory tract (Su et al., 2000) which is in agreement
with our observation. A higher expression of CYP2B6 was also
observed in MucilAir™ (Supplementary Fig. 1). CYP2B6 is a known
liver enzyme (Gonzalez et al., 1992), however, enzymes of the
CYP2B family (2B7/2B6) have also been detected in bronchial biop-
sies and tobacco nitrosamines are also known substrates for
CYP2B6 (Dicke et al., 2005). Those differences can explain the sep-
aration of MucilAir™ and HBECs/EpiAirway™ by PCA.
Following our initial gene expression proﬁling we extended
the culture time of MucilAir™ for three donors from 23 to
113 and 173 days and assessed metabolic gene proﬁles at each
time point. Principal component analysis and hierarchical clus-
tering (Fig. 5) did not cluster the expression proﬁles based on
time points. Since the gene expression was conducted with
three subjects, we cannot exclude that using a larger group
might have given more power to detect a time effect on gene
expression. Hence, we remain cautious and only conclude that
for this sample size and this gene panel we could not detect
a time effect. It is obvious from the heat map, however, that
overall, there was little change in the expression pattern of
the metabolic genes.
Finally, we assessed the activity of two pairs of CYPs involved
in the activation of inhaled tobacco smoke toxicants, namely
CYP2A6/13 and CYP1A1/1B1 (Chiang et al., 2011; Hodek et al.,
2013). We ﬁrst measured the metabolic activity of CYP2A6/2A13
and CYP1A1/1B1 in MucilAir™ from three donors maintained in
culture for less than one month (18 and 13 days post-delivery)
(Fig. 6). As expected CYP1A1/1B1 activity was detected in all three
donors after induction with TCDD and was inhibited by a-naph-
thoﬂavone, a CYP1A1/1B1 inhibitor (Fig. 6A). A clear coumarin 7-
hydroxylation activity was also observed and was suppressed in
the presence of the CYP2A6/2A13 inhibitor 8-methoxypsoralen
(Figs. 6B and 7). When the culture was extended to a period from
6 to 7 months inducibility and activity of CYPs could still be
detected (Fig. 8). Whilst the activity of CYP1A1/1B1 was very con-
sistent after induction over the period tested, more variability was
observed for CYP2A6/2A13. CYP2A6/2A13 activity beyond day 154
in culture was not tested. Microscopic inspection of MucilAir™
indicated a change in the culture morphology, including a reduc-
tion of ciliated areas which lead us to stop at day 154. It is possible
that repeat coumarin exposure might have altered the tissue mor-
phology over time as coumarin is a known lung toxicant (Lake,1999; Ratanasavanh et al., 1996). It is unclear whether the drop
in activity past day 143 is an experimental variation or was due
to the culture aging and treatment, either way, being able to main-
tain CYPs activity over an extended period of time in vitro is
remarkable.
One key challenge in toxicology testing in the 21st century is
to assess chemicals/mixtures for toxicity potential with less reli-
ance on animal models, but predictive of adverse biological
effects in humans. In this context, future evaluation of
MucilAir™ should be conducted with a variety of inhaled
environmental toxicants with different modes of action and
compared with in vivo data. For instance, the secretion of MUC
proteins is a well-documented in vivo response following
exposure to the cytotoxic gas acrolein in multiple species
(Borchers et al., 1998, 1999). Such response could be assessed
in MucilAir™. CYP-dependent activation of nitrosamines leads
to DNA-strand breaks and adduct formation in vivo (Holzle
et al., 2007) which could also be tested in reconstituted
respiratory epithelia. Interlaboratory reproducibility of simple
end points such as mucus secretion, % of ciliated area, and cilia
beat frequency with cells from multiple donors should also be
performed with and without exposure to toxicants. This step is
key to evaluate the robustness of the reconstituted airway
epithelia for regulatory testing. So far, the MucilAir™ model has
been successfully used to assess respiratory sensitizers (Huang
et al., 2013), respiratory absorption (Reus et al., 2014), and
toxicity of delivery vectors such as nanoparticles (Frieke et al.,
2015) highlighting its potential suitability for safety and efﬁcacy
evaluation of airborne substances. The long term maintenance
of the airway epithelia characteristics observed in this study
further support the value of MucilAir™ for safety/toxicological
evaluation in the context of repeated exposure.
In conclusion, we have conducted an extensive analysis of the
ASL proteomic and xenobiotic metabolizing gene expression pro-
ﬁle of MucilAir™. Key mucociliary protein markers and the ciliated
phenotype of the culture remained present over a period of a few
months. Xenobiotics metabolic enzyme expression and activity is
present and can be measured for an extended period of time. The
combined weight of evidence from proteomics, gene expression
and protein activity support that the MucilAir™ system is suitable
for repeat exposure of pro-toxicants.
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